Foghorn Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Foghorn Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 61% in 3 years; of every extra $100 of sales, $296 became extra profit. Higher than 90% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 99% of its market value (net cash). Higher than 88% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-139.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 86% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$296Sales grew 61% in 3 years; of every extra $100 of sales, $296 became extra profit.
Higher than 90% of Healthcare companies in United States.
Asset Productivity Ratio
+61% / -51%In 3 years sales changed by +61% while total assets changed by -51%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-93.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+99%Cash, after subtracting all debt, equals 99% of its market value (net cash).
Higher than 88% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Foghorn Therapeutics Inc. made a loss over the last year. Foghorn Therapeutics Inc. owes $1.40 for every $1 it owns. Foghorn Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossFoghorn Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-1.47Foghorn Therapeutics Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$119 MThe total market value of all of Foghorn Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeFoghorn Therapeutics Inc.'s net worth is negative ($81 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.40×Foghorn Therapeutics Inc. owes $1.40 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Dividend yield
NoneFoghorn Therapeutics Inc. does not currently pay a dividend.
Revenue growth
+37%Revenue rose 37% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Profit growth
LossFoghorn Therapeutics Inc. made a loss in each of the last two years.
Profit margin
-240.3%Foghorn Therapeutics Inc. lost $240 for every $100 of revenue.
Cash vs debt
Net cashFoghorn Therapeutics Inc. held $118 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Foghorn Therapeutics Inc. owe compared with what it owns?
Foghorn Therapeutics Inc. owes $1.40 for every $1 it owns, so it owes more than it owns, higher than 93% of Healthcare companies in United States.
Does Foghorn Therapeutics Inc. pay a dividend?
No. Foghorn Therapeutics Inc. does not currently pay a dividend.
Is Foghorn Therapeutics Inc.'s revenue growing?
Revenue rose 37% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.